Pulmonary arterial hypertension symptoms

Abrupt withdrawal or sudden large reductions in dosage may result in worsening of pulmonary arterial hypertension symptoms. 

Pulmonary arterial hypertension (PAH) For the treatment of PAH in patients with New York Heart Association (NYHA) Class II to IV symptoms to diminish symptoms associated with exercise. 

Mechanism of Action An antiplatelet that directly dilates pulmonary and systemic arterial vascular beds, inhibiting platelet aggregation. Therapeutic Effect Reduces symptoms of pulmonary arterial hypertension associated with exercise. Pharmacokinetics Rapidly, completely absorbed after subcutaneous infusion 91% bound to plasma protein. Metabolized by the liver. Excreted mainly in the urine with a lesser amount eliminated in the feces. Half-life 2-4 hr... 

Bosentan is an endothelin receptor antagonist. It antagonized endothelin (ET) receptor by binding to ET and ETg receptors in the endothelium and vascular smooth muscle. Bosentan is indicated in treatment of pulmonary arterial hypertension in patients with WHO class III and IV symptoms, to improve exercise ability, and decrease the rate of clinical worsening. 

Mecfianism of Action A prostaglandin that dilates systemic and pulmonary arterial vascular beds, alters pulmonary vascular resistance, and suppresses vascular smooth muscle proliferation. Therapeutic Effect Improves symptoms and exercise tolerance in patients with pulmonary hypertension delays deterioration of condition. Pharmacokinetics Protein binding 60%. Metabolized in liver. Primarily excreted in urine minimal elimination in feces. Half-life 20-30 min. 

There has been a sequential comparison of inhaled nitric oxide 40 ppm with aerosolized iloprost 14— 17 micrograms in 35 adults with primary pulmonary hypertension (125). Five of the patients had minor headache and facial flushing during inhalation of iloprost, but these symptoms were short-lived and abated a few minutes after the inhalation ended. One patient had mild jaw pain after aerosolized iloprost, but again this was shortlived. There was an unexpected increase in pulmonary artery pressure in 10 patients and vascular resistance in six patients who received nitric oxide. The authors were uncertain of the cause of this increase, as nitric oxide generally behaves as a vasodilator, but they noted that... 

For the growing number of patients with combined pulmonary hypertension and abnormal left ventricular hemodynamics, a careful hemodynamic study can help to delineate the subtleties of both diseases and response to therapies. Exercise catheterization is recommended in those patients with normal hemodynamics at rest, but with a pretest likelihood of PAH and/or other data suggesting exercise-induced symptoms, for instance, exercise echo or cardiopulmonary stress test. Unfortunately, to date there is no consensus as to the best exercise protocols for an appropriate hemodynamic assessment. Among those used include upright bicycle with neck pulmonary arterial (PA) lines at 75% predicted maximum exercise, supine bicycle, supine arm exercise, and supine volume loading. In all cases, it is essential to carefully measure PCWP, cardiac outputs, and PA pressures at consistent parts of the respiratory cycle, and not merely PA pressures. 

The majority of patients with pulmonary hypertension are largely asymptomatic until marked vascular alterations have developed. When blood flow through the pulmonary artery is obstructed over a long period of time, however, the clinical picture is predictable and markedly uniform. In general, the patients exhibit normal pulmonary function measurements, a low carbon monoxide diffusion capacity (DlCO), and marked hyperventilation that leads to hypocapnia and decreased serum bicarbonate concentrations. Additional symptoms include weakness, fatigue, exertional dyspnea, and chest pains upon exertion due to low cardiac output and hypoxemia. Occasionally, hoarseness, hemoptysis, and cyanosis occur. 

Pulmonary hypertension is, by definition, a state when the mean pulmonary arterial pressure at rest is >25 mm Hg. Symptoms of pulmonary hypertension include shortness of breath, dizziness, fainting, leg swelling and others. A recent study found 38% prevalence of pulmonary hypertension among ESRD patients. This condition was associated with a >2-fold increase in all-cause mortality independent of other risk factors [4]. Another study found up to 56% prevalence of pulmonary hypertension in ESRD patients [5]. Many factors contribute to its development. They include volume overload, left ventricular failure, arterial hypertension, vascular access (VA) flow and the complex metabolic changes of ESRD [6]. 

Symptoms of pulmonary hypertension include dyspnea on exertion, chest pain, palpitations, syncope, ascites and lower extremity edema. Anginal symptoms may occur and are thought to be due to increased RV oxygen demand, decreased right coronary artery perfusion due to decreased pressure difference between aorta and RV end diastolic pressure, and rare instances of compression of the left main coronary artery by the dilated pulmonary trunk. Right ventricular hypertrophy (RVH) correlates with EKG findings including RV... 

Left ventricular failure can occur due to hypertension, aortic valve disease or coronary artery disease. The symptoms are pulmonary oedema and breathlessness. 

---